Collegium Pharmaceutical Inc COLL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Collegium to Participate in Upcoming Investor Conferences
Collegium Announces $50 Million Accelerated Share Repurchase Program
Trading Information
- Previous Close Price
- $24.71
- Day Range
- $24.14–24.95
- 52-Week Range
- $21.43–50.79
- Bid/Ask
- $21.49 / $26.70
- Shares Outstanding
- 31.08M
- Market Cap
- $760.42M
- Volume/Avg
- 4 / 815,343
Key Statistics
- Price/Earnings (Normalized)
- 6.20
- Price/Sales
- 1.05
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 6.58%
Company Profile
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 423
Valuation
Metric | COLL |
|---|---|
Price/Earnings (Normalized) | 6.20 |
Price/Book Value | 2.56 |
Price/Sales | 1.05 |
Price/Cash Flow | 2.97 |
Price/Earnings
COLL
Financial Strength
Metric | COLL |
|---|---|
Quick Ratio | 0.76 |
Current Ratio | 1.01 |
Interest Coverage | 1.41 |
Quick Ratio
COLL
Profitability
Metric | COLL |
|---|---|
Return on Assets (Normalized) | 16.40% |
Return on Equity (Normalized) | 100.22% |
Return on Invested Capital (Normalized) | 29.41% |
Return on Assets
COLL
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|?$D@&SB> | LOCK|&$M$V | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|@LCpXdF@ | LOCK|wt^>@ | $50B | |||
| Haleon PLC ADR HLN | LOCK|t?n&W>? | LOCK|!q | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|SZf<#<? | LOCK|bm& | $34B | |||
| Viatris Inc VTRS | LOCK|?rW%&R | LOCK|>> | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|&&d | LOCK|ntg | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|tVCQ#n | LOCK|cQ | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|##>^!F | LOCK|dP^ | $4B | |||
| Perrigo Co PLC PRGO | LOCK|>p!QJs | LOCK|Q> | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|h&hgVJ$ | LOCK|N!ymQ | $2B |
United States